InvestorsHub Logo
Followers 39
Posts 2870
Boards Moderated 0
Alias Born 12/06/2003

Re: None

Tuesday, 05/08/2018 5:50:05 PM

Tuesday, May 08, 2018 5:50:05 PM

Post# of 1721
INSYS Therapeutics Announces Exclusive License Partnership with Lunatus to Commercialize SUBSYS(R) (fentanyl sublingual spray) in the Middle East

https://finance.yahoo.com/news/insys-therapeutics-announces-exclusive-license-200200022.html

Donald Trump and even Elizabeth Warren may be horrified that Arabs in agony from breakthrough cancer pain in their final days will get relief from a fentanyl mist that enters the bloodstream from the mouth with superfast relief.

Sorry, children, scream all you want. You aren't included.

“Partnering with Lunatus will make SUBSYS® available to adult cancer patients in the licensed territory who are suffering episodes of breakthrough cancer pain despite receiving around-the-clock opioid therapy,” said Saeed Motahari, president and chief executive officer of INSYS Therapeutics.

I am frankly a bit surprised by Subsys seemingly only used as a supplement to other opioid relief but I guess those Arabs don't worry as much about dying cancer patients losing their immortal souls to everlasting fiery torment. frown

Yes, yes, I know about deaths from opoid addiction but that is nearly all the business of other drugs than Insys' Subsys.

Best, Terry

Best, Terry
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.